Upregulation of stomatin is associated with poor prognosis and promotes tumor progression of orbital diffuse large B-cell lymphoma

Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma that predominantly affects the elderly and carries a poor prognosis. When arising in the orbit, DLBCL is characterized by rapid growth, high invasiveness, and a risk of severe vision loss. Despite the use of the R-CHOP regimen, long-term survival outcomes remain suboptimal, highlighting the need for new prognostic biomarkers and therapeutic targets.

Methods: We explored stomatin as a potential prognostic biomarker and therapeutic target for orbital DLBCL. Stomatin expression was analyzed using the GEO database (GSE83632), and Mendelian randomization (MR) analysis was conducted to assess its causal relationship with DLBCL. Immunohistochemistry (IHC) was performed on orbital DLBCL specimens to evaluate stomatin expression. The functional role of stomatin was examined through siRNA-mediated knockdown in DLBCL cell lines, followed by validation using quantitative RT-PCR and Western blot. Cell proliferation, invasion, migration, and apoptosis were assessed using CCK-8, Transwell assays, and flow cytometry.

Results: Database analysis revealed elevated stomatin expression in DLBCL, and MR analysis suggested a positive causal association with disease development. IHC confirmed significantly increased stomatin expression in orbital DLBCL tissues, which was associated with poor prognosis based on survival analysis. Vitro assays demonstrated that stomatin knockdown significantly inhibited cell proliferation, migration, and invasion while promoting apoptosis.

Discussion: Our findings indicate that stomatin contributes to orbital DLBCL progression and is associated with adverse clinical outcomes. Stomatin may serve as both a prognostic biomarker and a potential therapeutic target for this malignancy.

1 Introduction

Orbital lymphoma (OL) is the most common primary malignant tumor in the orbit, originating from lymphoid tissues within or surrounding the orbital region (1, 2). It accounts for approximately 55%–67% of orbital tumors, with incidence rates rising globally (3). Diffuse large B-cell lymphoma (DLBCL), the most common of non-Hodgkin’s lymphoma worldwide (4, 5),is the most frequent aggressive histological subtype of OL, comprising approximately 13.4% of cases (6). DLBCL is divided into two subtypes based on cell origin: Germinal Center B-cells (GCB) and Non-GCBs. Non-GCB subtype is more common, accounting for 59% to 75% of cases (7).DLBCL primarily affects adults, with incidence increasing with age (8). It is highly malignant and aggressive (8), especially in cases involving the orbital region, presenting significant clinical challenges. However, there is currently no effective treatment. Patients who undergo surgical resection often suffer from recurrence and metastasis. About 60% of patients only achieve remission with the standard R-CHOP chemotherapy regimen (including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). About 30%–40% of patients respond poorly, experiencing early relapse, drug resistance, or even mortality (9). These challenges highlight the urgent need for novel therapeutic targets to improve survival outcomes for DLBCL patients.

Stomatin is an integral protein found in the plasma membrane of human red blood cells (10). It was first identified through studies on hereditary stomatocytosis, which is a type of hemolytic anemia (11). Stomatin is recognized as a crucial component of the cell membrane, playing key roles in regulating the activity of various channels and transporters (12–14), forming lipid rafts, mediating lipid droplet formation (10, 15, 16), and participating in the regulation of inflammatory responses (17–19). Recent studies have shown that stomatin is abnormally expressed in various malignant tumors, although the findings are inconsistent (20–24). However, the functions and mechanisms of stomatin in tumor tissues remain unclear.

Here, we investigated the potential association between orbital DLBCL and stomatin protein expression. First, bioinformatics analysis and Mendelian randomization (MR) studies were used to predict the potential significance of stomatin in orbital DLBCL. We also analyzed stomatin protein expression in orbital DLBCL tumor tissues and examined its relationship with pathological features. Then we explored the association between stomatin protein levels and the prognosis of patients with orbital DLBCL. Finally, we investigated the specific effects of stomatin on tumor growth and progression, aiming to reveal the underlying regulatory mechanisms.

2 Materials and methods

2.1 Analysis of differential gene expression

We collected the GSE83632 dataset from the GEO database, which includes expression data from 76 DLBCL samples and 83 normal samples. After standardization and log₂ transformation, the data were analyzed for differences between normal and tumor tissues using the “limma” R package. Additionally, we calculated the expression levels of stomatin in various tissues.

2.2 MR analysis

The data for the stomatin gene were obtained from a comprehensive meta-analysis of blood eQTLs (25). Disease-related data were obtained from the OPEN GWAS database, specifically using the dataset labeled “Diffuse large B-cell lymphoma” (finn-b-C3_DLBCL). We established a significance threshold of 5 × 10–⁸ for the instrumental variables of the stomatin gene, including an LD coefficient (r²) of < 0.45 and independent SNPs with a physical distance greater than 10,000 kilobases (26). For our MR analysis, we used methods such as random effects inverse variance weighting (IVW), MR-Egger, and weighted median (WM) analyses. Primary results were derived using the IVW method, with statistical significance defined as P < 0.05. To assess pleiotropy, we employed MR-Egger regression, where a significant intercept (P < 0.05) indicates substantial pleiotropy (27). We also used Cochran’s Q statistic to test for heterogeneity; a significant Cochran’s Q (P < 0.05) indicates considerable heterogeneity in the effects of various genetic variations (28).

2.3 Patients

Between December 2008 and December 2014, thirty-six patients diagnosed with orbital DLBCL and treated with surgery at the Department of Orbital Diseases of the Third Medical Center of the Chinese PLA General Hospital (Beijing, China) and the Ophthalmology Center of Shandong Second Medical University Affiliated Hospital were enrolled in the study and followed up until January 2022. All studies involving human subjects were conducted following the principles of the Declaration of Helsinki and received approval from the Medical Ethics Committee of Weifang Medical University. All clinical samples were collected with written informed consent from the patients or their immediate family members.

Diagnosis of orbital DLBCL was confirmed by experienced pathologists for all patients. Among the patients, 29 (80.6%) had the ABC subtype and 7 (19.4%) had the GCB subtype. The cohort included 20 male and 16 female patients, aged 24 and 85 years (median age 60 years). Patients were followed up in person for at least 5 years to monitor recurrences.

2.4 Immunohistochemical staining

Surgically excised orbital tissues (classified as surgical discard) were fixed in 10% formalin for 12 hours and embedded in paraffin. Each sample was sectioned into two 4-μm slices and stained with an anti-stomatin antibody (Proteintech, Rosemont, USA). Erythrocyte staining served as an internal positive control. To verify the specificity of the staining, an immunohistochemical negative control was performed by replacing the primary antibody with PBS under the same experimental conditions. Two blinded senior pathologists independently assessed the stained sections. Stomatin-positive cells and staining intensity were evaluated in 10 randomly selected fields (100×magnification). The percentage of positive cells was categorized as 0 (≤5%), 1 (6%–25%), 2 (26%–50%), 3 (51%–75%), and 4 (75%). Staining intensity was scored as 1 (weak), 2 (moderate), and 3 (strong). The final score was calculated as the product of percentage and intensity scores, with low (final score <6) and high (final score ≥6) categories for stomatin expression (29).

2.5 Cell culture and transfection

OCI-Ly3 was cultured in OCI-Ly3 cell-specific medium (Pricella Life Science & Technology Co., Ltd, Wuhan, China), which contained 20% fetal bovine serum and 1% penicillin-streptomycin, mixed with RPMI 1640 medium. Cells were maintained at 37°C in a 5% CO₂ atmosphere with saturated humidity. Small interfering RNA (siRNA) targeting stomatin (GenePharma, Shanghai, China) was transfected into OCI-Ly3 cells using Lipofectamine 3000 (Thermo Fisher Scientific, MA, USA). Negative control (NC) siRNA (GenePharma, Shanghai, China) was transfected into cells as the control group. Si-stom (sense 5′-GCAGUCUACUCUGGAUGAUTT-3′, antisense 5′-AUCAUCCAGAGUAGACUGCTT-3′), and NC siRNA (sense 5′-UUCUCCGAACGUGUCACGUTT-3′, antisense 5′-ACGUGACACGUUCGGAGAATT-3′) were designed and synthesized by GenePharma.

2.6 Quantitative reverse-transcription PCR

After 24 hours of transfection with siRNA negative control (NC) and siRNA targeting stomatin (si-stom), total RNA was extracted using TRnaZol Reagent (New Cell & Molecular Biotechnology, Suzhou, China). Reverse transcription was performed to synthesize cDNA using the Primescript Master Mix (Perfect Real Time) kit (Takara Bio Inc, Shiga, Japan). Quantitative Reverse-Transcription PCR (qRT-PCR) amplification was conducted using the TB Green Premix Ex Taq II kit (Takara Bio Inc, Shiga, Japan). Equal amounts of reverse transcription products were mixed with other components to form a 10μl reaction system. Stomatin mRNA expression in OCI-Ly3 cells was normalized to GAPDH as the internal reference gene. Specific primers were synthesized by GenePharma (Shanghai, China): stomatin, forward 5′-AAAGGTGGAGCGTGTGGAAA-3′, reverse 5′-CTTCGGCTGCAATAACCTTGG-3′; GAPDH, forward 5′-AAGCTCATTTCCTGGTATGACAA-3′, reverse 5′-CTTACTCCTTGGAGGCCATGT-3′.

2.7 Cell proliferation assay

After 48 hours of transfection with siRNA, NC cells and si-stom cells were seeded in 96-well plates at a density of 5 × 10³ cells per well, with a volume of 100 μl per well. Ten microliters of CCK-8 (Beyotime Biotechnology, Shanghai, China) was added to each well, and the plates were incubated at 37°C for 4 hours. The absorbance at 450 nm was measured using a microplate reader.

2.8 Transwell assay for cell migration and invasion

After transfection, NC and si-stom cells were collected by centrifugation, resuspended in RPMI-1640 serum-free medium (Gibco, Thermo Fisher Scientific, MA, USA), and adjusted to a density of 1.5 × 10⁶ cells/ml. A 200 μl aliquot of the cell suspension was then added to the Transwell chambers (Corning, New York, USA). The cells were incubated at 37°C for 48 hours, after which they were collected for migration analysis. For the invasion assay, cells were resuspended in RPMI-1640 serum-free medium and seeded onto a polycarbonate membrane pre-coated with a uniform layer of Matrigel (Corning, New York, USA) in the Transwell chambers. The cell density was adjusted to 1.5 × 10⁶ cells/ml, and 200 μl of the cell suspension was added to each chamber. The cells were incubated again at 37°C for 48 hours. After incubation, the cells were fixed in 4% paraformaldehyde (Solarbio, Beijing, China) for 10 minutes and stained with 0.1% crystal violet (Solarbio, Beijing, China) for 15 minutes. The stained cells were observed under an inverted microscope at 200× magnification and photographed for analysis.

2.9 Apoptosis assays

After OCI-Ly3 cells were transfected with siRNA, NC and si-stom cells were collected, refreshed with new medium, and re-cultured for 48 hours. Apoptosis in the NC and si-stom cells was then assessed using the Annexin V-FITC/7-AAD Fluorescence Double Staining Apoptosis Detection Kit (Pricella, Wuhan, China).

2.10 Western blot

After transfection of OCI-Ly3 cells, NC and si-stom cells were collected, and proteins were extracted using RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China). The concentration of the target protein was determined using the BCA method, and equal amounts of protein were separated by SDS-PAGE. The proteins were transferred to a PVDF membrane at a constant current of 400 mA and blocked with blocking buffer (Boster, Wuhan, China). Membranes were incubated overnight with antibodies against stomatin (1:1000, Proteintech, Rosemont, USA) and β-actin (1:1000, Proteintech, Rosemont, USA). After washing with Tris-HCl-Tween buffered saline solution (TBST), the membranes were incubated at room temperature for 1 hour with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Proteintech, Rosemont, USA). Finally, the membranes were developed using Super ECL Plus chemiluminescent substrate (Applygen, Beijing, China), and images were analyzed using Image J.

2.11 Statistical analysis

Data analysis was conducted using GraphPad Prism v10.0, SPSS 25, and ImageJ software. Statistical analyses included unpaired t-tests and two-way ANOVA, with significance levels indicated in the corresponding figures. Spearman correlation coefficients were calculated to evaluate the relationships between two variables. The strength of correlation was calculated (r). P value < 0.05 was considered statistically significant.

3 Results

3.1 Analysis of differential gene expression

To better understand the role of stomatin in different tumor types, we first conducted a pan-cancer analysis of the stomatin gene. The results showed that the expression levels of stomatin vary across different tumor types (Supplementary Figure S1). The goal of this study is to explore the specific expression pattern of stomatin in orbital DLBCL, particularly in comparison to other tumor types, where stomatin exhibits relatively higher expression levels. Differential expression analysis of the GSE83632 dataset identified 1531 differentially expressed genes (adjusted p-value < 0.05 and |log₂FC| ≥ 0.5), and their expression is shown in a heatmap (Figures 1A, B). Among them, stomatin was highly expressed in tumor tissues, demonstrating a degree of specificity in DLBCL (Figure 1C).

Figure 1

Figure 1. The expression difference analysis and MR analysis of stomatin were carried out, based on GSE83632 dataset and OPEN GWAS database. (A) Volcano plot of differentially expressed genes between normal and tumor tissue in GSE83632 (Adjust-p value <0.05 and |log₂FC|≥0.5). (B) Heatmap of differentially expressed genes between normal and tumor tissue in GSE83632. (C) The expression levels of stomatin in DLBCL and normal tissues were analyzed by the GSE83632 dataset. (D) Sensitivity analysis for Mendelian randomization (scatter plot). (E) Sensitivity analysis for Mendelian randomization (forest plot).

3.2 MR analysis

To explore the causal relationship between the stomatin gene and DLBCL, we performed MR analysis. The aim of this analysis was to assess the potential causal relationship between stomatin and orbital DLBCL through genetic variation, thereby avoiding confounding factors that may exist in traditional observational studies. At the genome-wide level, we identified and screened 20 independent stomatin SNPs that were not in linkage disequilibrium. The IVW analysis showed a positive causal association between stomatin gene and DLBCL [OR = 1.40, 95% CI (1.01, 1.95), P = 0.04, which is statistically significant at P < 0.05]. As shown in Supplementary Table S1, the Q-pvalue from the IVW analysis was 0.91, indicating no evidence of heterogeneity. Additionally, the MR-Egger intercept test suggested that directional pleiotropy was unlikely to introduce bias (P = 0.14), confirming that pleiotropy was not present in our data (Figures 1D, E).

3.3 Patient outcomes and stomatin expression level correlated with clinical and pathological characteristics of orbital DLBCL

After a minimum follow-up of 5 years, 50% of patients (18/36) experienced tumor recurrence, and 44.4% (16/36) died from their tumors. The median disease-free survival was 27.5 months (range, 8–70 months), and the median overall survival was 49 months (range, 9–89 months). Only three patients received Rituximab treatment, of whom two patients received the R-CHOP regimen and one patient received the R-CVP regimen. None of the patients has a poor response to Rituximab. Immunohistochemical analysis showed that stomatin protein expression was localized to the cell membrane in all orbital DLBCL tissues, with varying rates of positive expression (Figures 2A, B). The percentage of the stomatin stained cells varied from 15% to 56% in these samples. The median proportion of stomatin stained cells was 37.5%. Out of 36 patients with ocular DLBCL, 18 showed low expression (final score <6) and 18 showed high expression (final score ≥6) of stomatin. Intraorbital tumor sections of patients with orbital MALT lymphoma, follicular lymphoma, orbital lymphoreactive hyperplasia, and orbital inflammatory pseudotumor were also stained. In orbital MALT lymphoma and follicular lymphoma, staining intensity was weaker and the proportion of stomatin stained cells was less than 10% (Figures 2C, D). In orbital lymphoreactive hyperplasia and orbital inflammatory pseudotumor, the proportion of stomatin-positive cells was less than 5% (Figures 2E, F).

Figure 2

Figure 2. Immunohistochemical staining of stomatin in orbital diseases. (A, B) Orbital diffuse large B-cell lymphoma. (C) Orbital MALT lymphoma. (D) Orbital follicular lymphoma. (E) Orbital lymphoreactive hyperplasia. (F) Inflammatory pseudotumor.

As shown in Table 1, there were 18 patients each with high and low stomatin expression. Stomatin expression was significantly higher in Ann Arbor stage II-IV tumors compared to stage I tumors (P=0.002). Furthermore, patients with low stomatin expression had a significantly lower recurrence rate than those with high stomatin expression (P=0.002). Additionally, high stomatin expression was associated with higher lactate dehydrogenase (LDH) levels (P=0.000).

Table 1

Table 1. Stomatin expression and its relationship with clinical pathological characteristics of 36 orbital DLBCL patients.

We also examined the expression of stomatin mRNA using qRT-PCR in the biopsied specimen of orbital lymphoma. The expression of stomatin mRNA and protein in orbital tumor tissue of patients with orbital DLBCL was significantly higher than that of orbital MALT lymphoma and orbital follicular lymphoma (P<0.05) (Figures 3A, B). It was found that the expression of stomatin mRNA is closely related to the expression of stomatin protein (r=0.9381, P<0.0001) (Figure 3C). The expression of stomatin mRNA was closely related to overall survival (r = -0.6272, P<0.0001) and disease-free survival (r = -0.6479, P<0.0001) (Figure 3D).

Figure 3

Figure 3. Stomatin mRNA and protein expression in orbital lymphoma and their correlation analysis. (A) Stomatin mRNA expression in orbital lymphoma tissue. (B) Stomatin protein expression in orbital lymphoma, quantified based on IHC results. (C) Correlation between stomatin mRNA expression and protein expression in orbital DLBCL tissue, with protein expression based on IHC scoring. (D) Correlation analysis showing the association between stomatin mRNA expression and overall survival (OS) as well as disease-free survival (DFS) in patients with orbital DLBCL. Correlation analysis revealed a significant negative correlation between stomatin mRNA expression and OS (r = -0.6272, P < 0.0001) as well as DFS (r = -0.6479, P < 0.0001). *P < 0.05, *** P < 0.001, **** P < 0.0001. NS, Not Significant.

3.4 Survival analysis

Univariate analysis showed significant associations between stomatin protein expression, Ann Arbor stage, and LDH levels with disease-free and overall survival in patients (Table 2). Multivariate analysis was first performed using a Cox regression model (Table 3) and further adjusted using a Bayesian regression model (Supplementary Tables S2, S3). The adjusted results indicated that Ann Arbor stage and stomatin expression were independent prognostic factors for both disease-free and overall survival (Figure 4). Survival analysis further revealed that patients with high stomatin expression had significantly shorter survival times than those with low expression (Figure 5).

Table 2

Table 2. Univariate analysis of clinicopathological factors for disease-free and overall survival of 36 orbital DLBCL patients.

Table 3

Table 3. Multivariate analysis of clinicopathological factors for disease-free and overall survival of 36 orbital DLBCL patients.

Figure 4

Figure 4. Results of multivariate survival analysis adjusted by Bayesian regression model. (A) Multivariate analysis results of disease-free survival in 36 patients with orbital DLBCL. (B) Multivariate analysis results of overall survival in 36 patients with orbital DLBCL. (LDH, lactate dehydrogenase) *Р < 0.05.

Figure 5

Figure 5. Survival analysis. (A) Disease-free survival of patients with low and high stomatin expression in orbital DLBCL. (B) Overall survival of patients with low and high stomatin expression in orbital DLBCL.

3.5 Cell transfection

To verify the promoting effect of stomatin protein on orbital DLBCL, we performed in vitro experiments to knock down the expression of stomatin in two DLBCL cell line. The transfection efficiency was validated at both the molecular and protein levels. The results of qRT-PCR and Western blot analyses showed that the expression of stomatin at both the mRNA and protein levels was significantly reduced in si-stom cells compared to NC cells after siRNA transfection. The difference was statistically significant (Figure 6).

Figure 6

Figure 6. SiRNA transfection results. (A) OCI-Ly3 cells after transfection with si-stom by qRT-PCR. (B) OCI-Ly3 cells after transfection with si-stom by Western blot. NC, negative control; si-stom, siRNA targeting stomatin. **P < 0.01, ***P < 0.001.

3.6 Cell proliferation ability

We used the CCK-8 assay to assess the cell proliferation ability of si-stom and NC cells after transfection. The results are shown in Figure 7A. The proliferation ability of si-stom cells was significantly reduced compared to NC cells within 5 days following stomatin gene knock down, indicating that stomatin has a promoting effect on the growth of DLBCL cells.

Figure 7

Figure 7. The effect of stomatin gene knockdown on cell phenotype. (A) The effect of stomatin gene knockdown on OCI-Ly3 cell proliferation assessed by the CCK-8 assay. (B) The effect of stomatin knockdown on OCI-Ly3 cell migration and invasion assessed by transwell assay. (C) The effect of stomatin knockdown on OCI-Ly3 cell apoptosis assessed by flow cytometry. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, Not Significant.

3.7 Cell invasion and migration ability

To further verify the promoting effect of stomatin protein on DLBCL, we conducted transwell experiments to assess the invasion and migration abilities of cells. The results, as shown in Figure 7B, indicate that after transfection, the invasion and migration abilities of si-stom cells were significantly weakened. These findings suggest that stomatin promotes the invasion and migration capabilities of DLBCL.

3.8 Cell apoptosis

To further elucidate the promoting effect of stomatin protein on DLBCL, we stained cells transfected with the stomatin gene using Annexin V-FITC and 7-AAD, and detected the effect of stomatin protein on cell apoptosis using flow cytometry. As shown in Figure 7C, Q1 represents necrotic cells, Q2 represents late apoptotic cells, Q3 represents early apoptotic cells, and Q4 represents live cells. The results showed that the apoptosis rate of si-stom cells was 30.21%, while the control group had an apoptosis rate of 20.74%. There was a significant difference between the experimental group and the control group, and the difference was statistically significant (P < 0.05).

4 Discussion

This study provides comprehensive evidence that stomatin promotes the growth and development of orbital DLBCL. Bioinformatics analysis revealed that stomatin is overexpressed in DLBCL patients relative to healthy individuals, highlighting its role in tumor promotion. MR analysis establishes a positive causal relationship between stomatin and DLBCL, further corroborating the role of stomatin in tumor growth and progression. Building on these findings, we conducted a series of in vitro experiments. The results regarding cell proliferation, invasion, migration, and apoptosis indicated that stomatin enhances tumor cell progression. We also found that stomatin expression is lower in orbital tumor tissues of patients with other types of B-cell lymphoma, suggesting its high specificity in orbital DLBCL. Our findings emphasize the importance of stomatin in DLBCL and suggest its potential as a therapeutic target.

Current research has identified abnormal stomatin expression in several types of malignant tumors; however, findings on its role remain inconsistent. In breast cancer, several studies suggest that reduced stomatin expression may be linked to poorer prognosis (21). Conversely, our findings indicate that high stomatin expression levels in orbital DLBCL tissues may be predictive of poor prognosis and are significantly associated with higher recurrence rates. These results suggest that stomatin could serve as a potential prognostic marker for patients with orbital DLBCL. In summary, these findings underscore the potential utility of stomatin as a prognostic marker across various cancer types.

Stomatin is a member of the stomain protein family along with stomatin-like protein 1 (SLP-1), stomatin-like protein 2 (SLP-2), stomatin-like protein 3 (SLP-3) and podocin, and stomatin also belongs to another superfamily, SPFH (Stomatin, Prohibitin, Flotillin, HflK/HflC domain), which share sequence similarities (10, 30, 31). Findings suggest that each member of the SPFH superfamily exerts a different role in tumor cells in a cell type-dependent manner (24). For example, SLP-2 can promote the progression of various tumors, such as pancreatic cancer, ovarian cancer, and gastric cancer, and its high expression is closely associated with poor prognosis (32–35). Interestingly, and this is coincident with the results of the current study, stomatin promotes the progression of DLBCL, and its overexpression in tumors serves as a marker of poor prognosis. Reports have claimed that SPFH superfamily member prohibitin, on the other hand, has both promotional and inhibitory effects on tumors (36–38). As for flotillin, another member of the SPFH superfamily, it has been reported that it is overexpressed in many cancers and promotes tumor growth (39–41). However, there is also a table in the literature showing that flotillin may have an inhibitory effect on cancers (42). In summary, the reasons for the discrepancy between the existing reports that stomatin can inhibit cancer development and the present study (20–24) may be the same as those of other members of the SPFH superfamily, which have different effects in different cellular environments, and it is worthwhile for us to continue to explore the specific mechanisms of the reasons for the discrepancy.

Metabolic reprogramming is an important way for tumors to maintain malignant vitality (43), and reprogramming lipid metabolism is critical for tumor growth and development (44–46). Studies have shown that reprogramming lipid metabolism plays an important role in the development of DLBCL, suggesting that targeting DLBCL lipid metabolism may be an important direction for the development of novel anticancer therapeutic strategies (47). Current research indicates that stomatin is involved in various physiological activities, including the generation and maturation of adipocytes (15). Given the potential role of stomatin in lipid metabolism, we hypothesize that stomatin may play a crucial role in reprogramming lipid metabolism in DLBCL. Therefore, targeting stomatin or its mediated lipid metabolism pathways may represent an important direction for the development of novel anticancer drugs and therapeutic regimens. Future studies could further explore the specific mechanisms of action of stomatin through lipid metabolic pathways in DLBCL, as well as evaluate the efficacy and safety of stomatin-based anticancer therapeutic strategies.

Given the potential role of stomatin in lipid metabolism, we hypothesize that stomatin may play a crucial role in reprogramming lipid metabolism in DLBCL. Therefore, targeting stomatin or its mediated lipid metabolism pathways may represent an important direction for the development of novel anticancer drugs and therapeutic regimens. Future studies could further explore the specific mechanisms of action of stomatin through lipid metabolic pathways in DLBCL, as well as evaluate the efficacy and safety of stomatin-based anticancer therapeutic strategies.

There are some limitations in our study. First, we did not validate the in vivo experiments in our present study. Because stomatin knockout mice do not develop an obvious phenotype in the physiological state (20, 48) and the mouse orbital tumorigenic model is not well developed. Currently, there is limited research on the establishment of intraocular lymphoma models (49–51), and no reports have been found on the establishment of an animal model for orbital lymphomas. The subcutaneous tumor-bearing mouse model is widely used in cancer research, as it allows for the validation of tumor biological characteristics in an in vivo environment. However, the space for tumor growth is very different between the subcutaneous area and the orbit. This limits the application of subcutaneous tumor-bearing mouse model in orbital tumor research. Second, we have only examined the expression of stomatin in orbital DLBCL tumor tissues. Due to the limited samples, we have not yet observed stomatin expression in DLBCL at other body sites. This will be investigated in future studies.

In conclusion, our study reveals that stomatin is overexpression in orbital DLBCL. Stomatin could promote tumor progression and maybe stomatin is a good therapeutic target for orbital DLBCL.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving humans were approved by The Medical Ethics Committee of Weifang Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

WC: Visualization, Project administration, Writing – original draft, Methodology, Writing – review & editing. JC: Writing – review & editing, Validation, Methodology, Resources, Project administration. WS: Software, Writing – review & editing, Formal Analysis, Methodology, Project administration. XLi: Writing – review & editing, Project administration, Methodology, Resources. JM: Methodology, Writing – review & editing, Software. XLiu: Writing – review & editing, Software. LX: Writing – review & editing, Resources. WZ: Funding acquisition, Supervision, Writing – review & editing, Conceptualization.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by Natural Science Foundation of Shandong Province (Grant No. ZR2023MH069), Weifang Health Commission Research Project (Grant No. WFWSJK-2023-163), Scientific Research Development Fund of the Affiliated Hospital of Shandong Second Medical University (Teaching Hospital) (Grant No. 2024FYM005) and Weifang Young Medical Talents Support Program. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1596614/full#supplementary-material

References

1. Strianese D, Laezza MP, Tortora F, Fusco G, de Divitiis O, D'Aponte A, et al. Long-term survival and factors associated with increased mortality in patients with ocular adnexal lymphomas. Cancers (Basel). (2024) 16:2252. doi: 10.3390/cancers16122252

PubMed Abstract | Crossref Full Text | Google Scholar

2. Alfaar AS, Yousef YA, Wilson MW, Hassanain O, Kakkassery V, Moustafa M, et al. Declining incidence and improving survival of ocular and orbital lymphomas in the us between 1995 and 2018. Sci Rep. (2024) 14:7886. doi: 10.1038/s41598-024-58508-7

PubMed Abstract | Crossref Full Text | Google Scholar

3. Zhang W, Rokohl AC, Guo Y, Yao K, Fan W, and Heindl LM. Global incidence and prevalence of Malignant orbital tumors. Adv Ophthalmol Pract Res. (2024) 4:128–33. doi: 10.1016/j.aopr.2024.04.002

PubMed Abstract | Crossref Full Text | Google Scholar

4. Musimar Z, Mpetani M, Abramson JS, Chabner BA, and Mohamed Z. Diffuse large B-cell lymphoma treated with R-chop in a resource-limited setting in South Africa: A real-world study. Oncologist. (2023) 28:e756–e64. doi: 10.1093/oncolo/oyad069

PubMed Abstract | Crossref Full Text | Google Scholar

5. Minghan Q, Shan W, Xinrui C, and Huaqing W. Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO annual meeting. Cancer Biol Med. (2022) 19:1117–20. doi: 10.20892/j.issn.2095-3941.2022.0403

PubMed Abstract | Crossref Full Text | Google Scholar

6. Akyildiz A, Ismayilov R, Rustamova N, Tokatli M, Koc I, Akin S, et al. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management. Ann Hematol. (2024) 103:905–15. doi: 10.1007/s00277-023-05569-9

PubMed Abstract | Crossref Full Text | Google Scholar

7. Shi Y, Xu Y, Shen H, Jin J, Tong H, and Xie W. Advances in biology, diagnosis and treatment of DLBCL. Ann Hematol. (2024) 103:3315–34. doi: 10.1007/s00277-024-05880-z

PubMed Abstract | Crossref Full Text | Google Scholar

8. Tavares A and Moreira I. Diffuse large B-cell lymphoma in very elderly patients: towards best tailored treatment - a systematic review. Crit Rev Oncol Hematol. (2021) 160:103294. doi: 10.1016/j.critrevonc.2021.103294

PubMed Abstract | Crossref Full Text | Google Scholar

9. Sehn LH and Salles G. Diffuse large B-cell lymphoma. N Engl J Med. (2021) 384:842–58. doi: 10.1056/NEJMra2027612

PubMed Abstract | Crossref Full Text | Google Scholar

10. Yokoyama H and Matsui I. The lipid raft markers stomatin, prohibitin, flotillin, and HflK/C (SPFH)-domain proteins form an operon with NfeD proteins and function with apolar polyisoprenoid lipids. Crit Rev Microbiol. (2020) 46:38–48. doi: 10.1080/1040841x.2020.1716682

PubMed Abstract | Crossref Full Text | Google Scholar

11. Lande WM, Thiemann PV, and Mentzer WC Jr. Missing band 7 membrane protein in two patients with high Na, low K erythrocytes. J Clin Invest. (1982) 70:1273–80. doi: 10.1172/jci110726

PubMed Abstract | Crossref Full Text | Google Scholar

12. Rougé S, Genetet S, Leal Denis MF, Dussiot M, Schwarzbaum PJ, Ostuni MA, et al. Mechanosensitive pannexin 1 activity is modulated by stomatin in human red blood cells. Int J Mol Sci. (2022) 23:9401. doi: 10.3390/ijms23169401

PubMed Abstract | Crossref Full Text | Google Scholar

13. Appelman MD, Robin MJD, Vogels EWM, Wolzak C, Vos WG, Vos HR, et al. The lipid raft component stomatin interacts with the Na(+) taurocholate cotransporting polypeptide (NTCP) and modulates bile salt uptake. Cells. (2020) 9:986. doi: 10.3390/cells9040986

PubMed Abstract | Crossref Full Text | Google Scholar

14. Klipp RC, Cullinan MM, and Bankston JR. Insights into the molecular mechanisms underlying the inhibition of acid-sensing ion channel 3 gating by stomatin. J Gen Physiol. (2020) 152:e201912471. doi: 10.1085/jgp.201912471

PubMed Abstract | Crossref Full Text | Google Scholar

15. Wu SC, Lo YM, Lee JH, Chen CY, Chen TW, Liu HW, et al. Stomatin modulates adipogenesis through the ERK pathway and regulates fatty acid uptake and lipid droplet growth. Nat Commun. (2022) 13:4174. doi: 10.1038/s41467-022-31825-z

PubMed Abstract | Crossref Full Text | Google Scholar

16. Salzer U and Prohaska R. Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts. Blood. (2001) 97:1141–3. doi: 10.1182/blood.v97.4.1141

PubMed Abstract | Crossref Full Text | Google Scholar

17. Zhu Z, Guo Z, Gao X, Chen Y, Huang J, Li L, et al. Stomatin promotes neutrophil degranulation and vascular leakage in the early stage after severe burn via enhancement of the intracellular binding of neutrophil primary granules to F-actin. Burns. (2024) 50:653–65. doi: 10.1016/j.burns.2023.12.013

PubMed Abstract | Crossref Full Text | Google Scholar

18. Zhang J, Tan J, Wang M, Wang Y, Dong M, Ma X, et al. Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD. Sci Adv. (2021) 7:eabh1541. doi: 10.1126/sciadv.abh1541

PubMed Abstract | Crossref Full Text | Google Scholar

19. Wu K and Wang L. Stomatin-knockdown effectively attenuates sepsis-induced oxidative stress and inflammation of alveolar epithelial cells by regulating CD36. Exp Ther Med. (2022) 23:69. doi: 10.3892/etm.2021.10992

PubMed Abstract | Crossref Full Text | Google Scholar

20. Rahman NIA, Sato A, Tsevelnorov K, Shimizu A, Komeno M, Ahmat Amin MKB, et al. Stomatin-mediated inhibition of the Akt signaling axis suppresses tumor growth. Cancer Res. (2021) 81:2318–31. doi: 10.1158/0008-5472.Can-20-2331

PubMed Abstract | Crossref Full Text | Google Scholar

21. Chen CY, Yang CY, Chen YC, Shih CW, Lo SS, and Lin CH. Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer. BMC Cancer. (2016) 16:697. doi: 10.1186/s12885-016-2681-7

PubMed Abstract | Crossref Full Text | Google Scholar

22. Arkhipova KA, Sheyderman AN, Laktionov KK, Mochalnikova VV, and Zborovskaya IB. Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer. (2014) 14:100. doi: 10.1186/1471-2407-14-100

PubMed Abstract | Crossref Full Text | Google Scholar

23. An H, Ma X, Liu M, Wang X, Wei X, Yuan W, et al. Stomatin plays a suppressor role in non-small cell lung cancer metastasis. Chin J Cancer Res. (2019) 31:930–44. doi: 10.21147/j.issn.1000-9604.2019.06.09

PubMed Abstract | Crossref Full Text | Google Scholar

24. Sato A, Rahman NIA, Shimizu A, and Ogita H. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment. Cancer Sci. (2021) 112:4005–12. doi: 10.1111/cas.15114

PubMed Abstract | Crossref Full Text | Google Scholar

25. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. (2021) 53:1300–10. doi: 10.1038/s41588-021-00913-z

PubMed Abstract | Crossref Full Text | Google Scholar

26. Li J, Yu Y, Sun Y, Yu B, Tan X, Wang B, et al. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: A mendelian randomization study. Cardiovasc Diabetol. (2023) 22:278. doi: 10.1186/s12933-023-02019-8

PubMed Abstract | Crossref Full Text | Google Scholar

27. Burgess S and Thompson SG. Interpreting findings from mendelian randomization using the MR-Egger method. Eur J Epidemiol. (2017) 32:377–89. doi: 10.1007/s10654-017-0255-x

PubMed Abstract | Crossref Full Text | Google Scholar

28. Deng X, Hou S, Wang Y, Yang H, and Wang C. Genetic insights into the relationship between immune cell characteristics and ischemic stroke: A bidirectional Mendelian randomization study. Eur J Neurol. (2024) 31:e16226. doi: 10.1111/ene.16226

PubMed Abstract | Crossref Full Text | Google Scholar

29. Zhu W, Li D, and Xiao L. Upregulation of valosin-containing protein (VCP) is associated with poor prognosis and promotes tumor progression of orbital B-cell lymphoma. Onco Targets Ther. (2019) 12:243–53. doi: 10.2147/ott.S182118

PubMed Abstract | Crossref Full Text | Google Scholar

30. Lapatsina L, Brand J, Poole K, Daumke O, and Lewin GR. Stomatin-domain proteins. Eur J Cell Biol. (2012) 91:240–5. doi: 10.1016/j.ejcb.2011.01.018

PubMed Abstract | Crossref Full Text | Google Scholar

31. Skryabin GO, Komelkov AV, Galetsky SA, Bagrov DV, Evtushenko EG, Nikishin II, et al. Stomatin is highly expressed in exosomes of different origin and is a promising candidate as an exosomal marker. J Cell Biochem. (2021) 122:100–15. doi: 10.1002/jcb.29834

PubMed Abstract | Crossref Full Text | Google Scholar

32. Chao D, Ariake K, Sato S, Ohtsuka H, Takadate T, Ishida M, et al. Stomatin−Like protein 2 induces metastasis by regulating the expression of a rate−Limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Oncol Rep. (2021) 45:90. doi: 10.3892/or.2021.8041

PubMed Abstract | Crossref Full Text | Google Scholar

33. Guo XY, Guo HF, and Guo HM. Clinical significance of SLP-2 in epithelial ovarian cancer and its regulatory effect on the notch signaling pathway. Eur Rev Med Pharmacol Sci. (2020) 24:1666–71. doi: 10.26355/eurrev_202002_20340

PubMed Abstract | Crossref Full Text | Google Scholar

34. Yang S, Huang Y, Zhang H, Wang F, Shao L, and Wang X. Effect and mechanism of action of SLP-2 on the apoptosis and autophagy of gastric cancer cells. Oncol Lett. (2021) 22:707. doi: 10.3892/ol.2021.12968

PubMed Abstract | Crossref Full Text | Google Scholar

35. Liu Q, Li A, Wang L, He W, Zhao L, Wu C, et al. Stomatin-like protein 2 promotes tumor cell survival by activating the JAK2-STAT3-PIM1 pathway, suggesting a novel therapy in CRC. Mol Ther Oncolytics. (2020) 17:169–79. doi: 10.1016/j.omto.2020.03.010

PubMed Abstract | Crossref Full Text | Google Scholar

36. Zhang J, Yin Y, Wang J, Zhang J, Liu H, Feng W, et al. Prohibitin regulates mTOR pathway via interaction with FKBP8. Front Med. (2021) 15:448–59. doi: 10.1007/s11684-020-0805-6

PubMed Abstract | Crossref Full Text | Google Scholar

37. Ding T, Xu H, Zhang X, Yang F, Zhang J, Shi Y, et al. Prohibitin 2 orchestrates long noncoding RNA and gene transcription to accelerate tumorigenesis. Nat Commun. (2024) 15:8385. doi: 10.1038/s41467-024-52425-z

PubMed Abstract | Crossref Full Text | Google Scholar

38. Barbier-Torres L and Lu SC. Prohibitin 1 in liver injury and cancer. Exp Biol Med (Maywood). (2020) 245:385–94. doi: 10.1177/1535370220908257

PubMed Abstract | Crossref Full Text | Google Scholar

39. Gauthier-Rouvière C, Bodin S, Comunale F, and Planchon D. Flotillin membrane domains in cancer. Cancer Metastasis Rev. (2020) 39:361–74. doi: 10.1007/s10555-020-09873-y

PubMed Abstract | Crossref Full Text | Google Scholar

40. Li X, Zhao S, Fu Y, Zhang P, Zhang Z, Cheng J, et al. miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting flotillin-2. Int J Biol Sci. (2021) 17:4327–39. doi: 10.7150/ijbs.64851

PubMed Abstract | Crossref Full Text | Google Scholar

41. Wei J, Wang R, Lu Y, He S, and Ding Y. Flotillin-1 promotes progression and dampens chemosensitivity to cisplatin in gastric cancer via ERK and AKT signaling pathways. Eur J Pharmacol. (2022) 916:174631. doi: 10.1016/j.ejphar.2021.174631

PubMed Abstract | Crossref Full Text | Google Scholar

42. Saldaña-Villa AK and Lara-Lemus R. The structural proteins of membrane rafts, caveolins and flotillins, in lung cancer: more than just scaffold elements. Int J Med Sci. (2023) 20:1662–70. doi: 10.7150/ijms.87836

PubMed Abstract | Crossref Full Text | Google Scholar

43. Yu Y, Jiang Y, Glandorff C, and Sun M. Exploring the mystery of tumor metabolism: Warburg effect and mitochondrial metabolism fighting side by side. Cell Signal. (2024) 120:111239. doi: 10.1016/j.cellsig.2024.111239

PubMed Abstract | Crossref Full Text | Google Scholar

44. Broadfield LA, Pane AA, Talebi A, Swinnen JV, and Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. (2021) 56:1363–93. doi: 10.1016/j.devcel.2021.04.013

PubMed Abstract | Crossref Full Text | Google Scholar

45. Bian X, Liu R, Meng Y, Xing D, Xu D, and Lu Z. Lipid metabolism and cancer. J Exp Med. (2021) 218:e20201606. doi: 10.1084/jem.20201606

PubMed Abstract | Crossref Full Text | Google Scholar

46. Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. (2023) 16:103. doi: 10.1186/s13045-023-01498-2

PubMed Abstract | Crossref Full Text | Google Scholar

47. Zhang Z, Zhao C, Yang S, Lu W, and Shi J. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma. . Lipids Health Dis. (2024) 23:20. doi: 10.1186/s12944-024-02017-z

PubMed Abstract | Crossref Full Text | Google Scholar

48. Zhu Y, Paszty C, Turetsky T, Tsai S, Kuypers FA, Lee G, et al. Stomatocytosis is absent in "Stomatin"-deficient murine red blood cells. Blood. (1999) 93:2404–10. doi: 10.1182/blood.V93.7.2404

PubMed Abstract | Crossref Full Text | Google Scholar

49. Touitou V, Daussy C, Bodaghi B, Camelo S, de Kozak Y, Lehoang P, et al. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci. (2007) 48:3223–9. doi: 10.1167/iovs.07-0008

PubMed Abstract | Crossref Full Text | Google Scholar

50. Li Z, Mahesh SP, Shen DF, Liu B, Siu WO, Hwang FS, et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res. (2006) 66:10586–93. doi: 10.1158/0008-5472.Can-06-1981

PubMed Abstract | Crossref Full Text | Google Scholar

51. Aronow ME, Shen D, Hochman J, and Chan CC. Intraocular lymphoma models. Ocul Oncol Pathol. (2015) 1:214–22. doi: 10.1159/000370158

PubMed Abstract | Crossref Full Text | Google Scholar